Phase 1b Escalating Study to Evaluate the Safety and Immunogenicity of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc) Administered Intradermally to Healthy Adults as a 3-Dose Primary Series and Booster
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 07 May 2017
At a glance
- Drugs Ricin vaccine (Primary)
- Indications Ricin poisoning
- Focus Adverse reactions
- 28 Feb 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 27 Dec 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 27 Dec 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.